Overview

Cladribine Venetoclax in Monocytic AML

Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Phase:
PHASE2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
The Leukemia and Lymphoma Society
Treatments:
Azacitidine
Cladribine
venetoclax